SESSION 5 2:30pm 3:45pm
|
|
- Rosanna Hart
- 5 years ago
- Views:
Transcription
1 SESSION 5 2:3pm 3:45pm Optimizing the Diagnosis, Treatment, and Management of Irritable Bowel Syndrome SPEAKERS Richard J. Saad, MD, MS Spencer Dorn, MD, MPH, MHA Presenter Disclosure Information The following relationships exist related to this presentation: Dr Saad has no financial relationships to disclose. Dr Dorn is an ad hoc consultants to Gerson Lehrman Group, Guidepoint Global and Coleman Research Group. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Learning Objectives Diagnose IBS and differentiate from other bowel disorders using established clinical guidelines Summarize the efficacy and safety of pharmacologic and nonpharmacologic treatment options for IBS Implement patient-specific methods for managing IBS symptoms and improving function and quality of life Irritable Bowel Syndrome: Making the Diagnosis Richard J. Saad, MD, MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology University of Michigan 3 Irritable Bowel Syndrome (IBS) Diverse subgroup of functional bowel disorders Variable chronic gastrointestinal symptoms Abdominal discomfort, bloating, diarrhea, constipation, difficult passage of food or feces, passage of mucus, nausea Result in disordered gastrointestinal functioning Movement and processing of food/stool, sensory/motor function, secretory function, brain-gut interaction Lack a structural abnormality Lack a defining biomarker Rely on fulfillment of diagnostic clinical criteria IBS: Epidemiology Global prevalence of 11% 1 US prevalence of 1% to 15% 2 F:M of 1.5-2:1 Ratio greatest for constipation Most prevalent in those aged years 3 Prevalence is inverse of socioeconomic status 4 1 Canavan C et al. Clinical Epidemiol. 214;4(6): Saito YA et al. Am J Gastroenterol. 22;97(8): Hungin AP et al. Aliment Pharmacol Ther. 25; 21(11): Minocha et al. Dig Dis Sci. 26;51(3):
2 IBS: Patient Impact Impairs quality of life Social, emotional, and physical dimensions Miss 1 activity/social event per week Willingness to give up 1 to 15 years of life for cure Impairs work Miss 8.5 to 21.6 days/year 12% stop working completely Cost to patient 15% to 43% buy OTC remedies 2/3 buy laxative, 1/3 more than 3 medications IBS: Impact on Health Care Outpatient 25% to 5% will see a primary care provider 3% of total direct health care costs ( $747- $7547/year) 2 to 3 visits/year During the initial year of diagnosis Average of 6 blood tests Average of 1 out-patient procedure Average of 1 radiological procedure Canavan C et al. Aliment Pharmacol Ther. 214;4(9): OTC=over the counter. Canavan C et al. Aliment Pharmacol Ther. 214;4(9): IBS: Impact on Health Care Inpatient Costs Based on National Inpatient Sample database Discharge diagnosis of IBS 11,433 12,842 Mean length of hospitalization 3.7 days 3.7 days Mean hospital charges (per hospitalization) $6,873 $21,153 Aggregate charge (national bill) $78.5 million $271 million Diagnostic Criteria for IBS: The Rome Criteria International working group of expert researchers and clinicians Diagnostic criteria created primarily for research purposes Most recent criteria published in 26 by Rome III Rome I (1992) Rome II (1999) Sethi S et al. Aliment Pharmacol Ther. 213;38(11-12): Rome III Criteria for IBS Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with 2 or more of the following: Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form of stool Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis Symptoms Supportive of IBS Abnormal stool frequency >3 BM/day or <3 BM/week Abnormal stool form lumpy/hard or loose/watery Fecal urgency Straining with defecation Sense of incomplete evacuation Passage of mucus Bloating Longstreth GF et al. Gastroenterology. 26;13(5): Wilkins T, et al. Am Fam Physician. 212 Sep 1;86(5): BM=bowel movement.
3 A More Practical Clinical Definition for IBS: Abdominal pain/discomfort occurring in association with altered bowel habits for 12 or more weeks IBS Subtypes Irritable bowel syndrome with constipation (IBS-C) Irritable bowel syndrome with diarrhea (IBS- D) Irritable bowel syndrome with alternating constipation and diarrhea (IBS-M) ACG Task Force. Am J Gastroenterol. 29;14(S1)S1-S35. IBS Subtypes Are Based on Stool Consistency Percentage of hard or lumpy stools IBS-C* IBS-U IBS-M IBS-D Percentage of loose or watery stools Adapted from Longstreth GF et al. Gastroenterology. 26;13(5): * Bristol Stool Form Scale 1-2 Bristol Stool Form Scale 6-7 IBS-M = IBS-mixed IBS-U = unclassified IBS Diagnosis - Overlap Between Chronic Constipation (CC) and IBS-C Chronic Constipation Abdominal Pain / Discomfort IBS With Constipation + D21 IBS vs CC Clinically: Diagnosis Overlap Between Functional Diarrhea and IBS-D IBS = abdominal discomfort present with or with constipation CC = abdominal discomfort occurs when constipation symptoms present - Abdominal Pain / Discomfort + Functional Diarrhea IBS With Diarrhea Adapted from Rome Foundation teaching slide D23
4 Paradigm Shift in the Diagnosis of IBS Historically a diagnosis of exclusion Now a diagnosis can be made based on fulfillment of symptom-based criteria and absence of alarm signs Diagnostic Studies to Consider in the Evaluation of IBS Symptoms Routine laboratory work CBC, CMP, ESR, CRP, TSH Antibody testing for celiac sprue Tissue transglutaminase Stool studies FOBT, O & P, C diff Hydrogen breath testing Glucose, lactulose, lactose, fructose Abdominal imaging X-ray, Ultrasound, CT, MRI Endoscopy Colonoscopy, EGD Pretest Probability of Organic Disease in IBS Pretest Probability in IBS (%) Prevalence in General Population (%) Colon cancer Colitis/IBD Thyroid disease Lactase Deficiency Celiac Disease Lesions Yield of Colonoscopy in Non-C IBS The prevalence of structural abnormalities is not higher in IBS-M and IBS-D IBS Patients (n=466) N (%) Controls (n=451) N (%) P value Adenomas 36 (7.7) 118 (26.1) <.1 Hyperplastic polyps 39 (8.4) 52 (11.5) NS Colorectal adenocarcinoma (.) 1 (.2) NS Inflammatory bowel syndrome 2 (.4) (.) NS Microscopic colitis 7 (1.5) NA N/A NS=not significant. Cash BD et al. Am J Gastroeneterol. 22;97(11): Chey WD et al. Am J Gastroenterol. 21;15(4): Evidence-based Testing in Clinical Practice Routine diagnostic testing not indicated Exception: serologic testing for celiac disease Directed testing in the setting of alarm features or failure of response to symptomdirected therapy Age-appropriate screening Brandt. Am J Gastroenterol. 22;97:S1-S26. Cash BD, Chey WD. Aliment Pharmacol Ther. 24;19(12): ACG Task Force. Am J Gastroenterol. 29; 14(S1):S1-S35. Alarm Features Age 5 Unintentional weight loss Family history GI malignancy Inflammatory bowel disease Celiac disease Severe (unrelenting) diarrhea Fevers, chills Travel to endemic area Nocturnal symptoms Blood in stool Anemia Lembo A, et al. N Engl J Med. 23;349: Brandt LJ, et al. Am J Gastroenterol. 25;1(suppl 1):S5-S21. Cash BD, et al. Rev Gastroenterol Disord. 27;7: GI=gastrointestinal.
5 Optimizing the Diagnosis of IBS 1. Make the diagnosis! Based on presence of IBS-defining symptoms in absence of alarm features Only pursue directed testing IBS Conceptual Model Visceral Life Hypersensitivity Stress Coping Skills 2. Provide an explanation for symptoms Provides rationale for additional testing and treatment 3. Provide reassurance Post-Infectious Permeability Microbiome Motility Social Support Immune regulation Pathophysiology: For Your Patient Your bowels are overly sensitive to environmental stimuli Food Hormones Stress This results in bowel dysfunction Disturbed muscle function Altered secretory function Lower pain threshold Probability of Underlying Organic Disease Incidence Is Low! Cohort of 149 IBS patients (95% in primary care setting): only.7% developed organic disease over 3-year period 1 UK study (n=2956): 1% with colorectal tumor and.6% with IBD within 1 year 2 UK study found cumulative incidence of 3.7% for CD, IBD, and CRC 15 years after IBS diagnosis (compared with 1.7% in controls) 3 1 Yawn BP et al. Am J Manag Care. 21;7(6): Garcia Rodriguez LA et al. Scand J Gastroenterol. 2;35(3): Canavan C et al. PLoS One. 214;9(9):e CD=celiac disease; CRC=colorectal cancer. Spencer Dorn, MD, MPH, MHA University of North Carolina School of Medicine Chapel Hill, North Carolina Patient-Provider relationship Lifestyle changes Diet, fiber, and probiotics CAM therapies Antispasmodics Antidepressants Psychological therapies Gut-specific IBS-D: Alosetron IBS-C: PEG, Lubiprostone, Linaclotide CAM, complementary and alternative medicine; IBS-C, irritable bowel syndrome with constipation; IBS-D, irritable bowel syndrome with diarrhea; PEG, polyethylene glycol.
6 Cornerstone of treatment Listen actively Determine reasons for visit Identify and respond to concerns and expectations Educate thoroughly Set realistic expectations Involve the patient in the treatment Positive physician-patient interaction reduces health care utilization and increases patient satisfaction Diary card symptom tracking can help identify exacerbating and alleviating factors and increase sense of control Moderate exercise for 2 to 6 minutes x 3 to 5 days/week improves IBS symptoms 11 Drossman DA et al. Gastroenterology. 22;123(6): ; Owens DM et al. Ann Intern Med. 1995;122(2): Dorn SD et al, Clin Gastroenterol Hepatol. 211;9(12): Johannesson E et al. Am J Gastroenterol. 211;16(5): Fermentable Oligo-, Di-, Monosaccharides And Polyols Among patients with IBS, diet is the #1 topic of interest 6% of subjects report that symptoms worsen after meals The act of eating as well as the specific foods consumed may be one of many factors that influences IBS Studying diet is quite challenging True food allergies are very rare General recommendations are possible, but diet should be tailored to the individual Excess Fructose Lactose Fructans Sorbitol Raffinose Honey, apples, pears, peaches, mangos, fruit juice, dried fruit Milk, ice cream, cheese, whey, curd Wheat (large amounts), rye (large amounts), onions, leeks, zucchini Apricots, peaches, artificial sweeteners and gums Lentils, cabbage, Brussels sprouts, asparagus, green beans, legumes Halpert A et al. Am J Gastroenterol. 27;12(9): ; Simrén M et al. Digestion. 21;63(2): ; Cremonini F,; Camilleri M. Gut. 23;52(5): ; Dainese R et al. Am J Gastroenterol. 1999;94(7): Shepherd SJ, Gibson PR. J Am Diet Assoc. 26;16(1): ; Gibson PR, Shepherd SJ. J Gastroenterol Hepatol. 21;25(2): RCTs N Fiber Response* Placebo RR of Unimproved Symptoms (95% CI) NNT (95%CI) Overall % 43%.87(.76-1.) 11 (5-1) Soluble % 36%.78 ( ) 6 (3-5) Insoluble % 46% 1.2 ( ) *Improved or resolved symptoms. Probiotics:live or attenuated microorganisms that have beneficial effects in humans Meta-analysis of 35 RCTs (n=3452) determined: Probiotics are effective therapies for IBS (global symptoms, pain, bloating, and gas) (NNT=7) We found evidence to support the use of combinations of probiotics as a group, although notfor any of the different combinations studied individually. CI, confidence interval; NNT, number needed to treat; RCTs, randomized, controlled trials; RR, relative risk. Ford AC et al. BMJ. 28;337:a2313. Ford AC et al. Am J Gastroenterol. 214 Oct;19(1):
7 Up to 5% of all patients with IBS use some sort of CAM Few CAM therapies have been rigorously evaluated for IBS: Peppermint Safe and moderately efficacious for pain Acupuncture Real and sham both more efficacious than placebo Smooth muscle relaxants with other anticholinergic effects Examples: dicyclomine, hyoscamine Meta-analysis of 22 RCTs comparing 12 different antispasmodics vs placebo (n=1778 patients) Significant heterogeneity among studies Symptoms persist in 39% of patients receiving antispasmodics vs 56% of placebo-treated patients (RR:.68; 95% CI: ) Appear most useful for abdominal pain Overall, these agents are cheap, widely available, and moderately efficacious for treating pain and bloating (and, possibly, urgency) Khanna R. et al. J Clin Gastroenterol. 214 Jul;48(6): Kaptchuk TJ et al. Plos One. 21 Dec 22;5(12). Ford AC et al. BMJ. 28;337:b1881. Tricyclic Antidepressants (TCAs): 9 studies (N=319 drug vs 256 control) Imipramine*, desipramine*, amitriptyline*, doxepin*; doses 1-15 mg Meta-analysis favors treatment Selective Serotonin Reuptake Inhibitors (SSRIs):5 studies (N=113 drug vs 117 control) Fluoxetine*, paroxetine*, citalopram*; dose 1-4 mg Meta-analysis favors treatment Putative mechanisms include: Central effects (antinociception, +/-anxiolysis and antidepressive) Peripheral effects (SSRIs reduce gut transit, TCAs are modestly anticholinergic) Anecdotally, it is essential to (a) discuss the rationale for these medications, (b) explain that patients may not see benefits for 4 to 6 weeks and that the dose may need to be adjusted *These agents are not currently US Food and Drug Administration approved for IBS. Ford AC et al. Gut. 29;58(3): RR NNT Trials N 95% CI 95% CI Cognitive behavioral therapy Relaxation training Dynamic psychotherapy Hypnotherapy Anecdotally, it is critical to (a) identify appropriate candidates and (b) explain the rationale for psychological therapy Ford AC et al. Gut. 29;58(3): Study N Female % Response: Alosetron, % 1. Camilleri M et al. Aliment Pharmacol Ther. 1999;13(9): Camilleri M et al. Lancet. 2;355(929): Camilleri M et al. Arch Intern Med. 21;161(14): Lembo T et al. Am J Gastroenterol. 21;96(9): Jones RH et al. Aliment Pharmacol Ther. 1999;13(11): Response: Placebo, % Therapeutic Gain, % Camilleri Camilleri Camilleri Lembo Jones Female patients with chronic, severe IBS-Dwho failed other treatments Patient education regarding possible serious adverse effects of severe constipation or ischemic colitis.95 cases of ischemic colitis/1 patient-years.36 cases of severe constipation/1 patient-years If ischemic colitis occurs, it is usually within the first month of therapy Prescribing program mandated by US Food and Drug Administration Requires patient to sign attestation form
8 Placebo (n=71) PEG 335+E (n=68) # SBMs Pain Level SBMs, spontaneous bowel movements. Chapman RW et al. Am J Gastroenterol. 213;18(9): PEG is an alcohol that is not absorbed through the gut lumen. It creates an osmotic gradient that drives water into the lumen 139 adults with IBS-C were randomized to placebo or PEG 335 plus electrolytes (PEG 335+E) During week 4 of treatment, PEG improved number of SBMs (P<.1), but not pain in IBS-C patients 5 Overall Responders (%) 25 *P= Lubiprostone 8 µg bid n= Placebo n=387 Drossman DA et al. Aliment Pharmacol Ther. 29;29(3): week treatment period Overall responder: Monthly responder for at least 2 of 3 months Monthly responder: At least moderate relief for 4/4 weeks or significant relief for 2/4 weeks Mean SBM Frequency per Month Phase 3 Studies Randomized Withdrawal/Extension Studies Baseline Month of Treatment P/L Group (n=179) Chey WD et al. Aliment Pharmacol Ther. 212;35(5): Change From Baseline L/P/L Group (n=8) Abdominal Pain/Discomfort Month of Treatment L/L Group (n=261) N=52 IBS-C patients who completed 12 or 16 weeks of a placebo-controlled phase 3 trial; patients enrolled in the extension study all received lubiprostone 8 µg bid. P, placebo L, lubiprostone % Adequate Relief: IBS Symptoms Most common AE diarrhea (19.7% vs 2.5%) AE, adverse event. *P<.1 NNT= Lin 29 mcg N=41 Chey WD et al. Am J Gastroenterol. 212;17(11): Placebo N=43 Patient-Provider relationship Lifestyle changes Diet, fiber, and probiotics CAM therapies Antispasmodics Antidepressants Psychological therapies Gut-specific IBS-D: Alosetron IBS-C: PEG, Lubiprostone, Linaclotide
Management of Functional Bowel Disorders
Management of Functional Bowel Disorders Amy Foxx-Orenstein, DO, FACG, FACP Professor of Medicine Mayo Clinic Tucson Osteopathic Medical Foundation May 1, 2016 Objectives Review epidemiology and pathophysiology
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationRome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC
Rome III Criteria for IBS Irritable Bowel Syndrome: What s the Latest? Tim Burke, DO Pacific Digestive Associates Clackamas, OR Recurrent abdominal pain or discomfort at least 3 days/month in the last
More informationWhat s the Latest? Rome III Criteria for IBS
Irritable Bowel lsyndrome: What s the Latest? American College of Gastroenterology Las Vegas, January 2014 Bi Brian E. Lacy, Ph.D., PhD M.D., MD FACG Professor of Medicine Geisel School of Medicine at
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationState of the Art: Management of Irritable Bowel Syndrome
ACG/FGS Annual Spring Symposium March 16-18, 2018 Bonita Springs, FL State of the Art: Management of Irritable Bowel Syndrome William D. Chey, MD Professor of Medicine University of Michigan IBS: Rome
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationRefractory IBS-D: An Evidence-Based Approach to Therapy
Refractory IBS-D: An Evidence-Based Approach to Therapy Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director, Northwestern Neurogastromotility, Functional, and Integrated Bowel
More informationDigesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options
Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options September 19, 213 Boston, Massachusetts Educational Partner: Session 3: Digesting the Facts in IBS: From Early Diagnosis
More informationWilliam D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology
Dietary and Other Non-pharmacological Management of IBS William D. Chey, MD, FACG Nostrant Professor of Medicine Director GI Nutrition Program University of Michigan Peter Loftus, May 2, 2016 Page 1 of
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More information4) Irritable Bowel Syndrome - Dr. Shaikhani. Epidemiology. Pathophysiology. Burden. Diagnosis
4) Irritable Bowel Syndrome - Dr. Shaikhani Epidemiology A common disorder, with a 7% prevalence. Women are 1.5 times more likely to be affected than men, most commonly between ages 20-40 years. Onset
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationPresenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018
Presenter Irritable Bowel Syndrome Current evidence for diagnosis & management Julie Daniels DNP, CNM Assistant Professor Course Coordinator of Primary Care of Women Faculty at Frontier Nursing University
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More informationIBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner
Rome IV: Diagnostic Criteria* IBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director Northwestern Functional
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Irritable bowel syndrome (IBS) has a variety of symptoms, most commonly cramping, abdominal pain, bloating, constipation, and diarrhea. Symptoms can vary from person to person,
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More information5 Things to Know About Irritable Bowel Syndrome
5 Things to Know About Irritable Bowel Syndrome Mike Kolber MD, CCFP, MSc PEIP 2017 Faculty/Presenter Disclosure Presenter: Mike Kolber Relationships that may introduce potential bias and/or conflict of
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationChronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016
Chronic Abdominal Pain Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016 Disclosures Speaker Bureau for Allergan Pharmaceuticals Abdominal Pain - Definitions Acute occurring for several
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationDisclosures. 4 th Annual Digestive Disease IBS: New Management Approaches. Early description of symptoms defining IBS 1849 W Cumming.
4 th Annual Digestive Disease IBS: New Management Approaches Disclosures Consultant Alkermes, Allergan, Forest, Ironwood, Prometheus, Salix Anthony Lembo, M.D. Beth Israel Deaconess Medical Center Harvard
More informationTreatment of IBS - Diet or Drugs?
Treatment of IBS - Diet or Drugs? Brooks D. Cash, MD, FACG Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Learning objectives Review the evolving
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationInflammatory or Irritable? (the bowel, not the speaker)
South GP CME Edgar Centre, Dunedin August 2014 Inflammatory or Irritable? (the bowel, not the speaker) Dr Jason Hill MBChB FRACP FRCP Edin Department of Gastroenterology, Southern DHB Dunedin School Of
More informationCurrent and Emerging Pharmacological Treatments in Irritable Bowel Syndrome
Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School What is the general
More informationSlide #43. Disclosure of Financial Relationships. IBS: Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine
Disclosure of Financial Relationships : Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Anthony Lembo,
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationWhy does my stomach hurt? Exploring irritable bowel syndrome
Why does my stomach hurt? Exploring irritable bowel syndrome By Flavio M. Habal, MD, PhD, FRCPC Case In this article: 1. What is IBS? A 45-year-old female is referred to your office with recurrent 2. How
More informationIRRITABLE BOWEL SYNDROME
IRRITABLE BOWEL SYNDROME CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Here are some questions to ask your doctor. WHAT IS IRRITABLE BOWEL SYNDROME? 4
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationEvolving Therapy in Irritable Bowel Syndrome (IBS)
Evolving Therapy in Irritable Bowel Syndrome (IBS) Dr. Syed Mohammad Arif MBBS, FCPS (Medicine), MD (Gastro) Associate Professor Department of Medicine Dhaka Medical College A good set of bowels is worth
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Irritable Bowel Syndrome Jeffrey Jump, MD CHI Memorial Integrative Medicine Associates Jeffrey_jump@memorial.org Chronic abdominal pain and altered bowel function in the absence
More informationObjectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose
Joshua D Noe, MD Associate Professor of Pediatric Gastroenterology Hepatology and Nutrition Medical College of Wisconsin I have no conflicts of interest to disclose Objectives Differentiate functional
More informationNew Insights into Functional Bowel Disorders. Diagnostic and Non medical Treatment Challenges in IBS
Presenter Disclosure Information 1:45 2:45pm New Insights into Functional Bowel Disorders The following relationships exist related to this presentation: William Chey, MD, AGAF, FACG, FACP, is a consultant
More informationWhat is Irritable Bowel Syndrome (IBS)?
What is Irritable Bowel Syndrome (IBS)? Irritable bowel syndrome (IBS) is a health issue found in your intestines (gut). IBS can cause symptoms such as: Belly pain. Cramping. Gas. Bloating (or swelling)
More informationIrritable Bowel Disease. Dr. Alexandra Ilnyckyj MD
Irritable Bowel Disease Dr. Alexandra Ilnyckyj MD Exactly what is IBS? Common condition affecting mostly women Symptoms are variable but they reflect altered gut movement (motility) and sensation Commonly
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care June 23, 2012 New York, New York Educational Partner: CME Incite, LLC Session 4: Under Pressure: The Need to Expedite IBS
More informationAn Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome
An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome American College of Gastroenterology August 2014, Indianapolis Brian E. Lacy, Ph.D., M.D. Professor of Medicine, Geisel School
More informationIrritable bowel syndrome in adults
Irritable bowel syndrome in adults NICE provided the content for this booklet which is independent of any company or product advertised Welcome In February 2008, NICE published a clinical guideline on
More informationIrritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center
Ti tl e s l i d e - p a rt 1 Irritable Bowel Syndrome and Chronic Constipation Susan Lucak, M.D. Columbia University Medical Center Treatment of IBS Abdominal pain / discomfort Antispasmodics Antidepressants
More informationIBS current status Peter Laszlo Lakatos
IBS current status Peter Laszlo Lakatos Semmelweis University 1st Department of Medicine Functional gastrointestinal disorders Chronic or fluctuating functional gastrointestinal symptoms that can not be
More informationDr. Melvyn Letier Constantiaberg Mediclinic October 2016
Dr. Melvyn Letier Constantiaberg Mediclinic October 2016 This presentation will enable you to: Understand the pathophysiology of IBS Recognize the clinical manifestations of IBS Make a confident diagnosis
More informationPsycho-pharmacologic Therapy. Objectives
Psycho-pharmacologic Therapy for Functional Bowel Disorders John J. Hutchings, M.D. Assistant Professor of Medicine and Psychiatry Louisiana i State t University it School of Medicine i Department of Medicine
More informationIrritable Bowel Syndrome. Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016
Irritable Bowel Syndrome Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016 Definition of Irritable Bowel Syndrome (IBS) Rome III Criteria Recurrent abdominal
More informationThe long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome Dr Miranda Lomer RD Email: miranda.lomer@kcl.ac.uk What is IBS - ROME IV Criteria A functional bowel disorder in which
More informationClinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61
Irritable bowel syndrome in adults: diagnosis and management Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationIBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center
IBS Dan Carter, M.D. Institute of Gastroenterology Sheba medical center Epidemiology Irritable bowel syndrome is a common functional gastrointestinal disorder that manifests as abdominal pain or discomfort
More informationWhat s New in IBS with Diarrhea. Dr. Geoffrey K. Turnbull, MD April 6, 2018.
What s New in IBS with Diarrhea Dr. Geoffrey K. Turnbull, MD April 6, 2018. Objectives To learn how to diagnose IBS with particular emphasis on patients who have diarrhea predominantly. Review management
More informationDisclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016
Disclosures Beating the Bowel Blues: An Update on the Treatment of Irritable Bowel Syndrome Matthew Nelson, PharmDBCPS, Roosevelt University College of Pharmacy Matthew Nelson declares no conflicts of
More informationLow FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015
Low FODMAP Dietary Approach For FGD/IBS Our Experience Charlotte McCamphill 19 th February 2015 CONTENTS What Is IBS What are FODMAPs Service Provision Audit Results Future Work WHAT IS IBS The Rome III
More informationIrritable Bowel Syndrome
68 TH ANNUAL MCGILL REFRESHER COURSE FOR FAMILY PHYSICIANS 2017 Irritable Bowel Syndrome Gad Friedman, MDCM, FRCPC Jewish General Hospital DISCLOSURES I have no disclosures LEARNING OBJECTIVES 1. Review
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care February 7, 2013 Fort Lauderdale, Florida Educational Partner: Session 4: Under Pressure: The Need to Expedite IBS Diagnosis
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care May 1, 2013 Anaheim, California Educational Partner: Session 5: Under Pressure: The Need to Expedite IBS Diagnosis and Treatment
More informationIrritable Bowel Syndrome and Chronic Constipation
Title slide - part 1 Irritable Bowel Syndrome and Chronic Constipation IBS - Physiologic Research Stress affects GI function Meals Pain / motility Time Line of Physiologic Research in IBS Pain sensitivit
More informationIrritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) Dr Rex J Polson 17 th January 2018 Overview Description of the condition Discussion of symptoms and investigations that may be required Discussion of management and treatment
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationDo Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief
More information10/1/2016. Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD. Kimberly Kearns, APN. Mary Davitt, PMHNP.
Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD Kimberly Kearns, APN Speakers Bureau: Medtronic Salix Pharmaceuticals Takeda Pharmaceuticals Mary Davitt, PMHNP None Rachel
More informationEvidence-based Treatment Strategies for
Evidence-based Treatment Strategies for Chronic Constipation William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria*: Chronic constipation Must include 2 of the following (>25%
More informationWhat Is the Low-FODMAP Diet?
LOW-FODMAP DIET What Is the Low-FODMAP Diet? FODMAP refers to a group of five sugars found in certain foods. These sugars are lactose, fructose (in excess), fructans, galactans and polyols. Specifically,
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Functional gastrointestinal disorders Definition A variable combination of chronic or recurrent gastrointestinal symptoms (attributed to the pharynx, esophagus, stomach, biliary
More informationStatement of Sponsorship and Support
Case Studies in the Practical Evaluation and Management of Irritable Bowel Syndrome with Diarrhea Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine
More informationFUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta
FUNCTIONAL DISORDERS TREATMENT ADVANCES Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta Name: Dr. Adriana Lazarescu Conflict of Interest Disclosure
More informationIBS-D: What to Do When Typical Treatment Methods Fail
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationFood is Medicine: A Nutritional Approach to IBS and More. Kathleen N. Mueller, M.D. CAFP Scientific Symposium 2017
Food is Medicine: A Nutritional Approach to IBS and More Kathleen N. Mueller, M.D. CAFP Scientific Symposium 2017 Nutritional approaches to IBS:FODMaP. New insight into food influences and gout. Breast
More informationIrritable Bowel Syndrome: Current and Emerging Treatment Options
Irritable Bowel Syndrome: Current and Emerging Treatment Options Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD INTRODUCTION Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome A Simple Tool for Identification and Dietary Management Dr Adrian Gilliland, GP and Clinical Advisor Primary Care, Capital and Coast DHB. Dr Rees Cameron, Gastroenterologist, Capital
More informationIrritable Bowel Syndrome 4/11/2017. New Insights in Irritable Bowel Syndrome. Overview
70 60 50 40 30 20 10 0 0 15 30 45 60 75 90 105 120 135 150 165 180 Time (Minutes) 4/11/2017 New Insights in Irritable Bowel Syndrome Christopher Chang, MD, PhD Division of Gastroenterology/Hepatology University
More informationGETTING REAL WITH GUT HEALTH
THE IMPORTANCE OF YOUR HEALTH STORY Reflections Do you regularly experience any of the following: Indigestion or food repeats on you after you eat Excessive burping or belching following meals Bloating
More informationManagement of the Refractory Functional GI Patient
Management of the Refractory Functional GI Patient Shanti Eswaran, MD Clinical Assistant Professor Division of Gastroenterology University of Michigan Ann Arbor, MI, USA Functional Bowel Disease A good
More informationIrritable Bowel Syndrome
What I need to know about Irritable Bowel Syndrome NATIONAL INSTITUTES OF HEALTH National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services What I need to know
More informationBowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care
Bowel cancer risk in the under 50s Greg Rubin Professor of General Practice and Primary Care Prevalence of GI problems in the consulting population Thompson et al, Gut 2000 Number of patients % of patients
More informationwith DIARRHEA (IBS-D)
Understanding IRRITABLE BOWEL SYNDROME with DIARRHEA (IBS-D) What is Irritable Bowel Syndrome with Diarrhea (IBS-D)? Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal disorder that involves
More informationIBS. Patient INFO. A Guide to Irritable Bowel Syndrome
Patient INFO IBS A Guide to Irritable Bowel Syndrome The information provided by the AGA Institute is not medical advice and should not be considered a replacement for seeing a medical professional. About
More informationIrritable bowel syndrome (IBS) is a chronic, potentially disabling
Evidence-Based Management of Irritable Bowel Syndrome With Diarrhea Mark Pimentel, MD Irritable bowel syndrome (IBS) is a chronic, potentially disabling disorder of the gastrointestinal (GI) tract with
More informationChronic diarrhea. Dr.Nasser E.Daryani Professor of Tehran Medical University
1 Chronic diarrhea Dr.Nasser E.Daryani Professor of Tehran Medical University Timing Acute diarrhea: 4 weeks Definitions Derived from Greek
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationIRRITABLE BOWEL SYNDROME
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 IRRITABLE BOWEL SYNDROME DEFINITION: *FUNCTIONAL GASTROINTESTINAL DISORDER CHARACTERIZED
More informationCME. Irritable Bowel Syndrome in the Older Adult. Etiopathogenesis. Introduction. Epidemiology
CME Irritable Bowel Syndrome in the Older Adult The online component of this CME learning activity is offered under the auspices of the CE department of the University of Toronto. Participating physicians
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationNW SMS icons. MFLN Intro
NW SMS icons The low FODMAP diet for irritable bowel syndrome: from evidence to practice Get handouts etc. by following the link below: learn.extension.org/events/3300 This material is based upon work
More informationIBS CLOSED REFERRAL STATUS: Dear Dr.,
Name: PHN/ULI: DOB: RHRN: RefMD: Dr. RefMD Fax: RefDate: Date Today: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS: Dear Dr., Referral Received Enhanced Primary Care Pathway CLOSED IBS The clinical and
More informationIBS and Functional GI Disorders (FGIDs)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/ibs-and-functional-gi-disorders-fgids/7424/
More informationDiagnosis and Treatment of Irritable Bowel Syndrome
Special Issue Diagnosis and Treatment of Irritable Bowel Syndrome Myung Gyu Choi, M.D. Department of Internal Medicine The Catholic University of Korea, College of Medicine Kangnam St. Mary's Hospital
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationThe relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary
The relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary Macintosh A 1, Wright-McNaughton M 1, Frampton C 2, Skidmore P 1, Gearry
More informationCanadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)
Journal of the Canadian Association of Gastroenterology, 2019, XX(X), 1 24 doi: 10.1093/jcag/gwy071 Original Article Original Article Canadian Association of Gastroenterology Clinical Practice Guideline
More informationIBS-D: The Role of Pathophysiology in Assessment and Treatment ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information